Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer.
Pulmonary Medicine Unit, Hôpital Larrey, Centre Hospitalier Universitaire Toulouse, , Université de Toulouse III,, 31 000 Toulouse, France.
Emilie
E
Bousquet
Allison
A
Zarbo
Emilie
E
Tournier
Christine
C
Chevreau
Julien
J
Mazieres
Mario E
ME
Lacouture
Vincent
V
Sibaud
D000279:Administration, Cutaneous; D000890:Anti-Infective Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D005148:Facial Dermatoses / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077594:Nivolumab; D012393:Rosacea / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab